Nebenwirkungen · Mounjaro
Mounjaro 2.5 mg solution for injection in pre-filled pen Mounjaro 5 mg solution for injection in pre-filled pen Mounjaro 7.5 mg solution for injection in pre-filled pen Mounjaro 10 mg solution for injection in pre-filled pen Mounjaro 12.5 mg solution for injection in pre-filled pen Mounjaro 15 mg solution for injection in pre-filled pen Mounjaro 2.5 mg solution for injection in vial Mounjaro 5 mg solution for injection in vial Mounjaro 7.5 mg solution for injection in vial Mounjaro 10 mg solution for injection in vial Mounjaro 12.5 mg solution for injection in vial Mounjaro 15 mg solution for injection in vial Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 11–12
HOS-148205 · Präparat HOS-099850
11 Overall, in phase 3 studies, the most common signs and symptoms of injection site reactions were erythema and pruritus. The maximum severity of injection site reactions for patients was mild (91 %) or moderate (9 %). No injection site reactions were serious.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:40:00Z · SHA-256 8d75eff2f10bd886e04a9cae39b5a53d6eea8dc5f9d2d23738f4b6def2646875 · Passage a4f031d450fd2c485425ba2fac9faf6111eb51d616800e097e78f0cdc51507c3 · Zeichen 12100–12362 im Abschnitt